îāļāđāļāļŦāļē
îž
î
āļĨāđāļāļāļāļīāļ
îāļāđāļāļŦāļē
î
Neurosense Therapeutics Ltd
NRSNîāđāļāļīāđāļĄāļĨāļāđāļāļĢāļēāļĒāļāļēāļĢāļāļīāļāļāļēāļĄ
0.465USD
-0.011-2.27%
āļāļīāļÂ 07-31 16:00ïžETïžāļĢāļēāļāļēāļĨāđāļēāļāđāļē 15 āļāļēāļāļĩ
15.15MāļĄāļđāļĨāļāđāļēāļāļĨāļēāļ
āļāļēāļāļāļļāļP/E TTM
āļĢāļēāļĒāļĨāļ°āđāļāļĩāļĒāļāđāļāļīāđāļĄāđāļāļīāļĄāļāļāļ Neurosense Therapeutics Ltd āļāļĢāļīāļĐāļąāļ
NeuroSense Therapeutics Ltd is an Israel-based clinical-stage pharmaceutical company. The Company is active in field of drug development and treatment offers Amyotrophic Lateral Sclerosis (ALS) patients, as well as other neurodegenerative diseases. The Company's lead product candidate, PrimeC, is an oral formulation of a fixed dose combination composed of a specific ratio of drugs. In addition to PrimeC, the Company has initiated research and development efforts in Alzheimer's disease and Parkinson's disease
āļāđāļāļĄāļđāļĨ Neurosense Therapeutics Ltd
îāļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļNRSN
āļāļ·āđāļāļāļĢāļīāļĐāļąāļNeurosense Therapeutics Ltd
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļDec 09, 2021
āļāļĩāļāļĩāđāļBen-Noon (Alon)
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ15
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļDec 09
āļāļĩāđāļāļĒāļđāđ11 Hamenofim St.
āđāļĄāļ·āļāļHERZLIYA
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ OMX - NASDAQ BASIC
āļāļĢāļ°āđāļāļĻIsrael
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ4672562
āđāļāļĢāļĻāļąāļāļāđ97297996183
āđāļ§āđāļāđāļāļāđhttps://www.neurosense-tx.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļNRSN
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļDec 09, 2021
āļāļĩāļāļĩāđāļBen-Noon (Alon)
āļāļđāđāļāļĢāļīāļŦāļēāļĢāļāļĢāļīāļĐāļąāļāļāļāļ Neurosense Therapeutics Ltd
îāļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
4.43M
+5.65%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
1.50M
+16.62%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
617.63K
+69.30%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
325.95K
+80.37%
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
207.90K
+88.46%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Ms. Caren Deardorf
Ms. Caren Deardorf
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Revital Mandil-Levin, Ph.D.
Dr. Revital Mandil-Levin, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
āļāļ·āđāļ
āļāļ·āđāļ/āļāļģāđāļŦāļāđāļ
āļāļģāđāļŦāļāđāļ
āļāļēāļĢāļāļ·āļāļŦāļļāđāļ
āđāļāļĨāļĩāđāļĒāļ
Mr. Alon Ben-Noon
Mr. Alon Ben-Noon
Chief Executive Officer, Director
Chief Executive Officer, Director
4.43M
+5.65%
Mr. Or Eisenberg
Mr. Or Eisenberg
Chief Financial Officer
Chief Financial Officer
1.50M
+16.62%
Dr. Ferenc Tracik
Dr. Ferenc Tracik
Chief Medical Officer
Chief Medical Officer
617.63K
+69.30%
Mr. Mark W. Leuchtenberger
Mr. Mark W. Leuchtenberger
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
325.95K
+80.37%
Mr. Cary J. Claiborne
Mr. Cary J. Claiborne
Non-Executive Independent Director
Non-Executive Independent Director
207.90K
+88.46%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
āļāļģāļāļēāļĄāļāļĩāđāļāļāļāđāļāļĒ
āđāļāļĢāļāļ·āļāļāļđāđāļāļ·āļāļŦāļļāđāļāļŦāđāļēāļāļąāļāļāļąāļāđāļĢāļāļāļāļ Neurosense Therapeutics Ltd?
îāļāļđāđāļāļ·āļāļŦāļļāđāļāļŦāđāļēāļāļąāļāļāļąāļāđāļĢāļāļāļāļ Neurosense Therapeutics Ltd āđāļāđāđāļāđ: Mr. Alon Ben-Noon
āļĄāļĩāļāļĩāđāļŠāļāļēāļāļąāļāļāļĩāđāļāļ·āļāļŦāļļāđāļāļāļāļ Neurosense Therapeutics Ltd (NRSN)?
îāļ āļ§āļąāļāļāļĩāđ 2026Q1 āļĄāļĩāļŠāļāļēāļāļąāļāļāļģāļāļ§āļ 33 āđāļŦāđāļāļāļĩāđāļāļ·āļāļŦāļļāđāļāļāļāļ Neurosense Therapeutics Ltd āđāļāļĒāļĄāļĩāļĄāļđāļĨāļāđāļēāļĢāļ§āļĄāļāļĢāļ°āļĄāļēāļ 367.79K āļāļīāļāđāļāđāļ 1.04% āļāļāļāļŦāļļāđāļāļāļąāđāļāļŦāļĄāļ āđāļĄāļ·āđāļāđāļāļĩāļĒāļāļāļąāļāļ§āļąāļāļāļĩāđ 2025Q4 āļāļēāļĢāļāļ·āļāļŦāļļāđāļāļāļāļāļŠāļāļēāļāļąāļāđāļāđāđāļāļīāđāļĄāļāļķāđāļ -2009158.00